Subtyping of renal cortical neoplasms in fine needle aspiration biopsies using a decision tree based on genomic alterations detected by fluorescence in situ hybridization.
OBJECTIVE
To improve the overall accuracy of diagnosis in needle biopsies of renal masses, especially small renal masses (SRMs), using fluorescence in situ hybridization (FISH), and to develop a renal cortical neoplasm classification decision tree based on genomic alterations detected by FISH.


METHODS
Ex vivo fine needle aspiration biopsies of 122 resected renal cortical neoplasms were subjected to FISH using a series of seven-probe sets to assess gain or loss of 10 chromosomes and rearrangement of the 11q13 locus. Using specimen (nephrectomy)-histology as the 'gold standard', a genomic aberration-based decision tree was generated to classify specimens. The diagnostic potential of the decision tree was assessed by comparing the FISH-based classification and biopsy histology with specimen histology.


RESULTS
Of the 114 biopsies diagnostic by either method, a higher diagnostic yield was achieved by FISH (92 and 96%) than histology alone (82 and 84%) in the 65 biopsies from SRMs (<4 cm) and 49 from larger masses, respectively. An optimized decision tree was constructed based on aberrations detected in eight chromosomes, by which the maximum concordance of classification achieved by FISH was 79%, irrespective of mass size. In SRMs, the overall sensitivity of diagnosis by FISH compared with histopathology was higher for benign oncocytoma, was similar for the chromophobe renal cell carcinoma subtype, and was lower for clear-cell and papillary subtypes. The diagnostic accuracy of classification of needle biopsy specimens (from SRMs) increased from 80% obtained by histology alone to 94% when combining histology and FISH.


CONCLUSIONS
The present study suggests that a novel FISH assay developed by us has a role to play in assisting in the yield and accuracy of diagnosis of renal cortical neoplasms in needle biopsies in particular, and can help guide the clinical management of patients with SRMs that were non-diagnostic by histology.
CancerGenetics, Inc., Rutherford, NJ, USA.
Banumathy
B
Gowrishankar
Lynnette
L
Cahill
Alexandra E
AE
Arndt
Hikmat
H
Al-Ahmadie
Oscar
O
Lin
Kalyani
K
Chadalavada
Seeta
S
Chaganti
Gouri J
GJ
Nanjangud
Vundavalli V
VV
Murty
Raju S K
RS
Chaganti
Victor E
VE
Reuter
Jane
J
Houldsworth
D044963:Biopsy, Fine-Needle / Q000379:methods*; D002869:Chromosome Aberrations; D003663:Decision Trees; D003936:Diagnosis, Computer-Assisted / Q000379:methods*; D005260:Female; D023281:Genomics / Q000379:methods*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007680:Kidney Neoplasms / Q000145:classification* / Q000235:genetics / Q000601:surgery*; D008297:Male
algorithm; classification; fine needle aspiration biopsies; fluorescence in situ hybridization; oncocytoma; renal cell carcinoma